On June 28, 2017 CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, reported the treatment of the first patient in the PROCLAIM-CX-2009 study (Probody Clinical Assessment In Man), a Phase 1/2 clinical trial evaluating CX-2009 as monotherapy in patients with select advanced solid tumors (Press release, CytomX Therapeutics, JUN 28, 2017, View Source [SID1234519705]). CX-2009 is a Probody drug conjugate (PDC) that targets CD-166, an antigen that is broadly and highly expressed in many types of cancers and is the first PDC to enter the clinic.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The unique targeting ability of our Probody platform allows us to pursue targets not accessible to conventional antibody drug conjugates. With CX-2009, we are leveraging the high levels of CD-166 on many types of cancer cells despite its presence on normal tissue," said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics. "By targeting CD-166 and localizing the activity of the CX-2009 Probody therapeutic to the tumor, we could potentially treat a number of cancers for which few, if any, treatment options exist."

About CX-2009 and the PROCLAIM-CX-2009 Trial
CX-2009, a PDC that targets cell surface protein CD-166, is being developed for the treatment of solid tumors. CD-166 is highly and homogeneously expressed on multiple tumor types, such as breast cancer, endometrial cancer and prostate cancer. CytomX has demonstrated that CD-166 effectively internalizes antibody-drug conjugates resulting in potent cell killing in-vitro. CX-2009 is designed to target CD-166 specifically in the tumor microenvironment and deliver the tubulin-destabilizing maytansine payload, DM4, to cancer cells. In 2014, CytomX entered into a license agreement with ImmunoGen, Inc. to develop PDCs against a defined number of targets, bringing together CytomX’s proprietary antibody masking technology and tumor-selective protease substrates with ImmunoGen’s highly potent antibody drug conjugate cell-killing agents and engineered linkers. CX-2009 is wholly owned by CytomX.

CX-2009 is being studied within PROCLAIM, CytomX’s international modular umbrella clinical trial program that encompasses the Phase 1/2 development of multiple Probody therapeutics. PROCLAIM-CX-2009 is a dose-finding Phase 1/2 study evaluating CX-2009 as monotherapy in patients with select cancer types, including non-small cell lung cancer, breast cancer, ovarian cancer, endometrial cancer, cholangiocarcinoma (bile duct cancer), head and neck cancer and castration-resistant prostate cancer. The objectives of the study are to establish the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of CX-2009.

More information about the trial is available at ClinicalTrials.gov.